Transkaryotic touts trial results

Transkaryotic Therapies said that a late-stage trial of its drug for Hunter syndrome demonstrated a statistically significant improvement for patients. The company says the results clears the way for an expected license application by the end of the year in Europe and the US. The news boosted shares of Shire, which is buying Transkaryotic. "Patients with Hunter syndrome are now one step nearer to being able to obtain treatment for this debilitating and life threatening condition with the release of this new trial data from TKT," said Shire chief executive, Matthew Emmens.

- read this report from ShareCast

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.